Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab

Inclusion Criteria: * Histologically confirmed invasive breast cancer * T1c-3 N0-2a * Confirmed of hormonal receptor status * HER2 positive confirmed by IHC 3+ or FISH+ * LVEF \> 50% by echocardiogram or MUGA * Adequate EKG * No prior treatment for breast cancer * PS 0-1 * Required baseline laboratory data WBC \> 4,000/mm3 and Neut \> 2,000/mm3 PLT \> 100,000/mm3 Hb \> 9.0g/dl AST and ALT \< ULNx2.5 T-Bil \< 1.5mg/dl Serum creatinin \< 1.5mg/dl * Written informed consent Exclusion Criteria: * With history of hypersensitivity reaction for important drug in this study * With history of invasive breast cancer * Bilateral invasive breast cancer * Patients with medical conditions that renders them intolerant to primary chemotherapy and related treatment, including infection, diarrhea, intestinal paralysis, severe Diabetes Mellitus * Positive for HBs antigen and with history of HVB * With history of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction, poorly controlled hypertension * With severe edema * With severe peripheral neuropathy * With severe psychiatric disorder * Pregnant or nursing women * Cases who physician judged improper to entry this trial